ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1089

The Budgetary Impact of Point-of-Care Hemoglobin Testing for Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Ficociello, Linda, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Rosen, Melissa M., Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Mullon, Claudy, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
  • Kossmann, Robert J., Fresenius Medical Care North America, Waltham, Massachusetts, United States
  • Costanzo, Mark, Fresenius Medical Care Renal Therapies Group, Waltham, Massachusetts, United States
Background

Point of care (POC) testing in dialysis clinics can improve the quality of care provided to end-stage renal disease (ESRD) patients. The objective of this study was to estimate the budgetary impact of transitioning from weekly lab-based analysis of hemoglobin from each dialysis session to POC testing.

Methods

A budget impact model with a 1-year time horizon was developed. Our model included costs of POC testing in real-time in dialysis clinics compared to requiring the shipment of 3 blood samples per month to a lab for analysis. A non-invasive monitoring technology, the Crit-Line monitor ® (CLM) measures hematocrit. Hemoglobin levels can be calculated from the measured hematocrit value. CLM is already used for fluid management in dialysis clinics and can also be used for POC testing. The model took the perspective of a healthcare organization responsible for providing dialysis treatments. The 2020 Medicare reimbursement value for a hematocrit test was used as a proxy value for lab testing costs. Our model also included costs associated with shipping, blood collection tubes, and erythropoiesis-stimulating agent (ESA) which is indicated for the treatment of anemia. Labor costs were excluded as they were considered fixed costs and would not change if POC testing was implemented.

Results

By replacing three blood draws per month, the use of a Crit-Line monitor® to assess hemoglobin levels could save $16.82 USD per patient per month.

Conclusion

The use of Crit-Line monitor® technology for point of care assessment of hemoglobin levels can result in decreased resource use and costs savings of $16.82 USD per patient per month compared to lab-based testing. Point of care testing may also have environmental benefits by reducing emissions associated with shipping samples and decreasing packaging needed to ship samples to a lab for analysis.

Funding

  • Commercial Support –